Inflammation Center, Infectious Diseases, Helsinki University Hospital and University of Helsinki, Finland.
Aava Travel Clinic, Medical Centre Aava, Finland.
Clin Infect Dis. 2020 Jan 2;70(2):210-218. doi: 10.1093/cid/ciz182.
One-third of the 100 million travelers to the tropics annually acquire extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE), with undefined clinical consequences.
Symptoms suggesting Enterobacteriaceae infections were recorded prospectively among 430 Finnish travelers, 90 (21%) of whom acquired ESBL-PE abroad. ESBL-PE isolates underwent polymerase chain reaction-based detection of diarrheagenic Escherichia coli (DEC) pathotypes (enteroaggregative E. coli [EAEC], enteropathogenic E. coli [EPEC], enterotoxigenic E. coli [ETEC], enteroinvasive E. coli, and Shiga toxin-producing E. coli), and extraintestinal pathogenic/uropathogenic E. coli (ExPEC/UPEC). Laboratory-confirmed ESBL-PE infections were surveyed 5 years before and after travel.
Among the 90 ESBL-PE carriers, manifestations of Enterobacteriaceae infection included travelers' diarrhea (TD) (75/90 subjects) and urinary tract infection (UTI) (3/90). The carriers had 96 ESBL-producing E. coli isolates, 51% exhibiting a molecular pathotype: 13 (14%) were DEC (10 EAEC, 2 EPEC, 1 ETEC) (12 associated with TD) and 39 (41%) ExPEC/UPEC (none associated with UTI). Of ESBL-PE, 3 (3%) were ExPEC/UPEC-EAEC hybrids (2 associated with diarrhea, none with UTI). Potential ESBL-PE infections were detected in 15 of 90 subjects (17%). The 10-year medical record survey identified 4 laboratory-confirmed ESBL-PE infections among the 430 travelers, all in subjects who screened ESBL-PE negative after returning home from their index journeys but had traveled abroad before their infection episodes.
Half of all travel-acquired ESBL-producing E. coli strains qualified molecularly as pathogens. Extraintestinal and uropathogenic pathotypes outnumbered enteric pathotypes (41% vs 14%), yet the latter correlated more closely with symptomatic infection (0% vs 92%). Despite more ESBL-PE strains qualifying as ExPEC/UPEC than DEC, travel-acquired ESBL-PE are more often associated with TD than UTI.
每年前往热带地区的 1 亿旅行者中,有三分之一会感染产生extended-spectrum β-lactamase (ESBL)的肠杆菌科细菌(ESBL-PE),但其临床后果尚不清楚。
430 名芬兰旅行者中前瞻性地记录了提示肠杆菌科感染的症状,其中 90 人(21%)在国外感染了 ESBL-PE。对 ESBL-PE 分离株进行基于聚合酶链反应的致腹泻性大肠埃希菌(DEC)病原型(聚集性大肠埃希菌[EAEC]、肠致病性大肠埃希菌[EPEC]、肠毒性大肠埃希菌[ETEC]、肠侵袭性大肠埃希菌和产志贺毒素大肠埃希菌)和肠外致病性/尿路致病性大肠埃希菌(ExPEC/UPEC)检测。对旅行前后 5 年的实验室确诊 ESBL-PE 感染进行了调查。
90 名 ESBL-PE 携带者中,肠杆菌科感染的表现包括旅行者腹泻(TD)(75/90 例)和尿路感染(UTI)(3/90 例)。携带者有 96 株产 ESBL 的大肠埃希菌分离株,其中 51%表现出分子病原型:13 株(14%)为 DEC(10 株 EAEC、2 株 EPEC、1 株 ETEC)(12 株与 TD 相关)和 39 株(41%)为 ExPEC/UPEC(无与 UTI 相关)。在 ESBL-PE 中,有 3 株(3%)为 ExPEC/UPEC-EAEC 杂种(2 株与腹泻相关,无与 UTI 相关)。在 90 名受试者中,有 15 名(17%)检测到潜在的 ESBL-PE 感染。10 年的医疗记录调查在 430 名旅行者中发现了 4 例实验室确诊的 ESBL-PE 感染,所有感染均发生在旅行者从旅行地返回后筛查 ESBL-PE 阴性但在感染前曾出国旅行的旅行者中。
所有旅行相关的产 ESBL 大肠埃希菌分离株中,有一半在分子上符合病原体标准。肠外和尿路病原型的数量超过肠病原型(41%比 14%),但后者与症状性感染的相关性更强(0%比 92%)。尽管更多的 ESBL-PE 分离株符合 ExPEC/UPEC 而不是 DEC,但旅行相关的 ESBL-PE 更常与 TD 相关,而不是 UTI。